Delve into Sanofi's "play to win" strategy as investments are ramping up after their consumer health division's divestment.

Opella is Sanofi’s consumer healthcare business unit focusing on ... Its portfolio primarily encompasses products related to Pain and inflammation, Digestive wellness, Allergy, Cough, cold ...

Janney Montgomery Scott LLC lessened its stake in Sanofi (NASDAQ:SNY – Free Report) by 0.3% in the third quarter, according ...

It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments ... and established prescription products.

Sanofi India net profit down 46% in quarter ended September 30: Our Bureau, New Delhi Friday, November 8, 2024, 11:35 Hrs [IST] Sanofi India has registered 46 per cent decline in ...

Sanofi is now in “exclusive negotiations” with U.S. private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50% controlling stake in its consumer health business Opella. With the French ...

Together, CD&R and Sanofi will support Opella’s growth strategy as a pure-play, global, and fast-moving consumer healthcare company ... third parties nor do we endorse or guarantee their products. We ...

The French government has taken a small stake in Sanofi's consumer healthcare business Opella, following political backlash about the pharmaceutical company's deal with a US private equity firm.

The French government has taken a small stake in Sanofi's consumer healthcare business Opella, following political backlash about the pharmaceutical company's deal with a US private equity firm.